Immunomedics, Inc.

NASDAQ: IMMU
$85.53
+$0.19 (+0.2%)
Closing price September 18, 2020
Gilead Sciences would not be the first company to pile on more debt to make an acquisition, but it is now eating deep into its cash for this acquisition.
Immunomedics shares more than doubled on Monday after the firm announced that it would be acquired by Gilead Sciences in one of the biggest deals to go down in the health care sector this year.
Monday's top analyst upgrades and downgrades included Adobe, BP, FedEx, GameStop, Gilead Sciences, Kroger, MGM Resorts, Micron Technology, Nvidia and Tradeweb Markets.
With the market showing the potential for some sizable rotation, the research team at BofA Securities has added Medtronic to the firm's US 1 List of top stocks to buy. It and three other US 1 health...
BofA Securities has made huge changes to its US 1 list of top stocks to buy. These five additions should fare well in the second half of 2020.
Immunomedics shares jumped on Thursday after the company announced a key update from the FDA for its breast cancer treatment Trodelvy.
Tuesday's top analyst upgrades and downgrades included BHP, Electronic Arts, Gilead Sciences, Immunomedics, KeyCorp, Peloton Interactive, Shopify, Sunnova Energy, Take-Two Interactive and Walt Disney.
Immunomedics shares soared on Monday after the announcements that a late-stage breast cancer study was halted early and a new chief executive officer was named.
Immunomedics shares made a handy gain on Thursday after the company announced that the FDA has accepted its Biologics License Application for its breast cancer treatment.
Here are five health-care-related stocks that recently saw their 50-day moving average cross above the 200-day average, a golden cross.
Immunomedics shares dropped sharply on Monday after the firm presented interim data from its midstage bladder cancer study at the European Society for Medical Oncology (ESMO) Annual Congress in...
The top analyst upgrades, downgrades and initiations seen on Monday included Alector, Bed Bath & Beyond, Dillard's, Foot Locker, Hasbro, Kraft Heinz, Vale, Xilinx and Zoetis.
Immunomedics, Signet Jewelry, Nautilus, and Lexicon Pharmaceuticals had all posted new 52-week lows by noon Friday.
Immunomedics shares were crushed on Friday after the firm received disappointing news from the FDA on its breast cancer treatment.
The top analyst upgrades, downgrades and other research calls from Monday include Ctrip.com, Goldman Sachs, Johnson & Johnson, Medtronic, Morgan Stanley, Yelp and Yum China.